Janssen Bets On Simeprevir For HCV In China; Partners With Hepatology Society
This article was originally published in PharmAsia News
Executive Summary
It may take four to five years for next-generation oral hepatitis C therapies to take hold in China, and Johnson & Johnson subsidiary Janssen Inc. isn’t wasting any time stepping up efforts to increase disease awareness via partnerships.